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a b s t r a c t
Mucopolysaccharidosis type I (MPS I), is an autosomal recessive lysosomal storage disorder caused by a deﬁciency in the α-L-iduronidase enzyme, resulting in decreased enzymatic activity and accumulation of glycosaminoglycans. The disorder phenotypically manifests with increased urine glycosaminoglycan excretion, facial
dysmorphology, neuropathology, cardiac manifestations, and bone deformities. While the development of new
treatment strategies have shown promise in attenuating many symptoms associated with the disorder, the
bone phenotype remains unresponsive. The aim of this study was to investigate and further characterize the skeletal manifestations of the Idua-W392X knock-in mouse model, which carries a nonsense mutation corresponding
to the IDUA-W402X mutation found in Hurler syndrome (MPS I-H) patients. μCT analysis of the
microarchitecture demonstrated increased cortical thickness, trabecular number, and trabecular connectivity
along with decreased trabecular separation in the tibiae of female homozygous Idua-W392X knock-in
(IDUA−/−) mice, and increased cortical thickness in male IDUA−/− tibiae. Cortical density, as determined by
μCT, and bone mineral density distribution, as determined by quantitative backscattered microscopy, were
equivalent in IDUA−/− and wildtype (Wt) bone. However, tibial porosity was increased in IDUA−/− cortical
bone. Raman spectroscopy results indicated that tibiae from female IDUA−/− had decreased phosphate to matrix
ratios and increased carbonate to phosphate ratios compared to Wt female tibiae, whereas these ratios remained
equivalent in male IDUA−/− and Wt tibiae. Femora demonstrated altered geometry and upon torsional loading to
failure analysis, female IDUA−/− mouse femora exhibited increased torsional ultimate strength, with a decrease
in material strength relative to Wt littermates. Taken together, these ﬁndings suggest that the IDUA−/− mutation
results in increased bone torsional strength by altering the overall bone geometry and the microarchitecture
which may be a compensatory response to increased porosity, reduced bone tensile strength and altered physiochemical composition.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Abbreviations: MPS I, mucopolysaccharidosis type I; IDUA, α-L-iduronidase; GAGs,
glycosaminoglycans; μCT, microcomputed tomography; BMDD, bone mineral density
distribution; FWHM, full width at half maximum; BV/TV, bone volume/total volume;
SMI, structure model index; Tmax, torsional ultimate strength; Su, tensile strength; U,
energy to failure; Ks, stiffness; G, shear modulus of elasticity; BMD, bone mineral density.
⁎ Corresponding author at: Departments of Biochemistry and Child Health, University of
Missouri, 117 Schweitzer Hall, Columbia, MO 65211, United States.
E-mail address: phillipscl@missouri.edu (C.L. Phillips).
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Mucopolysaccharidosis type I (MPS I; MIM# 252800) is an autosomal recessive lysosomal storage disorder caused by a deﬁciency in the
lysosomal enzyme α-L-iduronidase (EC 3.2.1.76), which catalyzes the
degradation of the glycosaminoglycans (GAGs), dermatan sulfate and
heparan sulfate [1]. The clinical severity of MPS I is dependent upon
α-L-iduronidase activity, which can vary widely and has been categorized into three distinct phenotypic subtypes: MPS I-Hurler (MPS I-H;
MIM# 607014), MPS I-Scheie (MPS I-S; MIM# 607016), and MPS I-
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Hurler/Scheie (MPS I-H/S; MIM# 607015), with the clinical severity
ranging from MPS I-H being the most severe subtype to MPS I-S being
the least severe. The incidence of MPS I-H is estimated to occur in
1:100,000 births [2]. The accumulation of GAGs results in progressive
cellular damage and visual impairment, hearing loss, cardiac manifestations, organomegaly, developmental delay with subsequent progressive
cognitive decline initiated by age 2 in severe MPS I-H patients [3]. Furthermore, MPS I-H patients present with severe skeletal abnormalities
through poorly understood mechanisms [4]. The skeletal abnormalities
are collectively known as dysostosis multiplex, and consist of stiffness
and contracture of joints, enlarged skull, genu valgum, thoracolumbar
kyphosis, hip dysplasia, abnormally shaped vertebrae and ribs, hypoplastic epiphyses and short stature [5–8]. As a result of the skeletal manifestations, MPS I-H patients typically undergo multiple high-risk
surgical interventions to delay the progression of the skeletal disease
and improve quality of life [9–11]. Novel therapeutic treatments such
as bone marrow or umbilical cord blood transplantation and weekly enzyme replacement are currently being used to sustain overall enzyme
activity and have improved and extended the quality of life of Hurler
patients. However, these treatments are unable to fully prevent development of the skeletal manifestations in Hurler patients [9,12]. Therefore, despite these therapeutic gains, MPS-I patients continue to
endure the consequences of disabling, painful bone disease that often
require rigorous surgical intervention.
In contrast to the two previously reported Idua knock-out mouse
models, Idua−/− and MPS I [13,14], the Idua-W392X knock-in mouse
model carries a nonsense mutation corresponding to the IDUA-W402X
mutation, commonly found in Hurler syndrome patients [15]. Wang
et al. showed that the phenotype of Idua-W392X mouse model parallels
that of human MPS I-H disease, which includes GAG accumulation due
to loss of α-L-iduronidase activity, cardiac manifestations and bone abnormalities such as broadening of the face, thickening of the zygomatic
arch and atypical femur length and width [15]. Even though the existing
animal models have been useful in evaluating various therapeutic approaches such as enzyme replacement therapy [16], bone marrow
transplantation [17,18], and gene therapy [19,20], much of the molecular mechanisms leading to the pathology remain to be elucidated. Although it has been shown that the Idua-W392X presents with typical
skeletal ﬁndings of MPS I-H [15,21], the whole bone biomechanical
and material properties have not been evaluated. The paucity in understanding the pathogenic mechanisms responsible for the musculoskeletal manifestations likely contributes to the absence of improvement in
the bone phenotype with the current therapies.
The goal of this study was to evaluate the microarchitecture, physiochemical composition and biomechanical integrity of the IduaW392X knock-in mouse model, in order to better deﬁne the underlying
biomechanical properties of the skeletal abnormalities and to begin to
elucidate the physiochemical mechanisms. Femora and tibiae from
wildtype (Wt), heterozygous Idua-W392X (IDUA+/−) and homozygous
Idua-W392X (IDUA−/−) 16 week old mice were evaluated on the basis
of whole bone biomechanical integrity and material properties. This
study highlights the microarchitectural, physiochemical, and biomechanical basis of the MPS I-H skeletal phenotype and can be used to
drive forward the design and improvement of current and future therapies to improve the bone quality of MPS I-H patients.
2. Methods
2.1. Animals and tissue harvest
The Idua-W392X mice were a generous gift from Dr. Kim Keeling,
University of Alabama at Birmingham, Alabama [15]. Idua-W392X
mice were previously backcrossed into a C57BL/6J congenic background
[17]. IDUA+/− breeding pairs and their offspring were housed in an
AAALAC accredited facility at the University of Missouri-Columbia and
had ad libitum access to water and food (Purina 5008 Formulab Diet;

Purina Mills Inc., St. Louis, MO). This study was performed under an approved University of Missouri Animal Care and Use Protocol. The
breeders and offspring were genotyped as previously described [17]
and weighed weekly starting at 5 weeks of age. The mice were raised
to 16 weeks of age (peak bone mineral density [22]), sacriﬁced, and
femora and tibiae were excised, the soft tissue removed, and the
bones wrapped in sterile 1 × PBS soaked gauze and stored at − 20 °C
until analyzed.
2.2. Tibial microarchitecture analysis
The macro- and microarchitecture of the left tibiae was determined
by microcomputed tomography (μCT) with the vivaCT 40 (Scanco Medical AG, Bassersdorf, Switzerland) as previously described [23] using
55 kVp X-ray tube potential, 145 μA current, 10 μm voxel resolution,
and 200 ms integration time to assess cortical bone and trabecular
bone properties. By hydroxyapatite calibration, the voxel values were
converted to a mineral-equivalent value, milligrams per cubic centimeter (mg/cm3). Three dimensional images of the tibiae were reconstructed along the long axis with series of 10 μm-thick slices, using a global
threshold of 253 (μCT gray value). The tibial cortical density and thickness were evaluated in the transverse plane at the mid-shaft starting
1 mm proximal to the ﬁbula–tibia junction. The proximal metaphysic
trabecular bone was analyzed 1 mm below the growth plate, and the
following determined: the bone volume fraction (BV/TV), trabecular
bone density, thickness, number, separation, connectivity density,
which describes abundance of trabecular connections, and the structure
model index (SMI), which describes shape of individual trabecular bone
ranging from 0 (perfect plate) to 3 (cylindrical rods) [24,25].
2.3. Tibial bone mineral density distribution and porosity
Quantitative backscattered scanning electron microscopy of left
tibias was used to characterize the bone mineral density distribution
(BMDD) and porosity. Tibiae were scanned in a digital electron
microscope containing a four-quadrant semiconductor backscattered
detector (Evo, Ziess, Germany). Imaging was performed at a 20 kV accelerating voltage, saturated ﬁlament current, 0.5 nA probe current
measured with a Faraday cup and a working distance of 12 mm. Magniﬁcation settings, store resolution and scan speed were kept consistent
between different imaging sessions to result in a pixel size of 760 nm.
Several high magniﬁcation images were taken from the cross section
of each sample and the images were combined using an image processing software (Image composite editor, Microsoft Research) to form the
whole bone cross section. To calibrate the backscattered signal, pure
carbon and aluminum standards (Micro-Analysis Consultants, UK)
were imaged in each scan and at the same condition of imaging the
bone. Calibration standards were imaged in several intervals while
scanning the bone. After imaging, the graylevel numbers of standards
were averaged between each two subsequent images of the phantom
to account for the signal variations. In a post-processing analysis and
to keep the scale of the graylevel histograms consistent between images, graylevel numbers of the bone and phantom were expanded linearly such that carbon and aluminum were 25 and 225, respectively. A
histogram containing the incidence of graylevel numbers was calculated for each sample and the mode and the full width at half maximum
(FWHM) of the histograms were determined. The bone porosity was
determined by excluding regions with cracks and microcracks from
the bone cross-section and then determining the fraction of the bone
area with lacunae and blood vessels relative to the total bone area
(Fig. 3A–C).
2.4. Bone mineral and matrix composition
Following μCT analyses the left tibia was sliced across the diaphyseal
midshaft and the cortical bone cross-sections were evaluated by Raman
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spectroscopy using a LabRam HR 800 Raman spectrometer (Horiba
JobinYvon, Edison, NJ). Raman spectroscopy uses molecular vibrational
techniques to evaluate the chemical properties (structure and composition) of the mineral and organic matrix components of bone. Averaged
bone biochemical composition was determined from Raman spectra
(700 to 1800 cm−1 range) that were excited by a helium-neon laser
(633 nm) with a 50 × water immersion objective as previously described [23], allowing acquisition of peaks attributed to the bone minerals and proteins. For each tibia the midshaft cortical cross-section
was examined at 4 points (anterior, posterior, medial and lateral) and
the data averaged for each sample. Spectra analyses were performed
to measure the area of hydroxyapatite ν1 PO3−
peak (960 cm−1), type
4
−1
2−
B ν1 CO3 peak (1070 cm ), and matrix CH2 band (1450 cm−1) and
3−
amide I [23]. The ratios of carbonate/phosphate (CO2−
3 /PO4 ), mineral
3−
to matrix (PO3−
4 /CH2), and mineral to collagen (PO4 /amide I) were
assessed.
2.5. Femoral μCT and torsional loading to failure
Prior to bone biomechanical testing, the right femoral geometric
parameters were evaluated by μCT analyses (MicroCAT II, Siemens
Medical). The image slices were reconstructed using the Amira 5.3.3
software package (Mercury Computer Systems/TGS) as previously
described [23] to give a cubic voxel dimension of 0.083 mm3. The
mid-shaft slice was modeled as a hollow elliptical cross-section with
periosteal (p) and endosteal (e) anterior–posterior (dp and de; minor
diameters) and medio-lateral (Dp and De; major diameters, and q =
De / Dp). Each femora was potted into a customized single use holder
with an exposed femur test length of 7 mm, and then subjected to torsional loading to failure analyses as previously described using the TAHDi testing machine (Stable Micro Systems, Surrey, UK) [23]. Applied
torque T (Nmm) was determined and evaluated as a function of relative
angular displacement θ (degrees) (Fig. 6A). The whole bone parameters,
torsional ultimate strength (Tmax, Nmm), strain energy to failure
(U, Nmm) and torsional stiffness (Ks, Nmm/rad), take into account
both the material the bone is comprised of and the size and shape of
the bone. The bone material properties, tensile strength (Su, N/mm2;
Su = [16Tmax / (πDpd2p(1 − q4))] and shear modulus of elasticity, (G,
N/mm2 ; shear modulus of elasticity = torsional stiffness × 7 mm /
polar moment of area), were assessed as previously described [23].
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stabilize the variation, a non-parametric ranked analysis was performed
according to Conover et al. [28]. Data are presented as mean ± standard
error (SE). Differences were considered to be statistically signiﬁcant at
p ≤ 0.05.
3. Results
3.1. Growth curves
Both male and female IDUA−/− mice were inherently heavier than
their Wt and IDUA+/− littermates at 16 weeks of age (Fig. 1). Growth
curves indicated that male IDUA−/− mice began to diverge from their
Wt and IDUA+/− littermates at 10 weeks of age (Fig. 1A). Female
IDUA−/− mice also began to diverge from their Wt littermates at 10
weeks, but did not become signiﬁcantly heavier than their IDUA+/− littermates until 16 weeks of age (Fig. 1B). Sex-matched Wt and IDUA+/−
littermates had similar weights at 16 weeks of age (Fig. 1). These ﬁndings were consistent with the previous study by Russell et al. [29]. In
order to determine if the effect of the Idua-W392X mutation on the
bone is independent of the increase in body weight, the following
microarchitecture, geometric, and biomechanical data were evaluated
by analysis of covariance with body weight as the covariate.
3.2. Microarchitecture
Evaluation of the skeletal microarchitecture determined that tibiae
from female IDUA−/− mice had increased cortical thickness (Table 1),
as well as increased trabecular number (Fig. 2D) and connectivity density (Fig. 2F), and a subsequent decrease in trabecular separation
(Fig. 2E) compared to their Wt and IDUA+/− littermates. Sixteen week
old male IDUA−/− tibiae exhibited similar trends, but only cortical
thickness reached signiﬁcance (Table 1). The tibiae of IDUA+/− mice
were equivalent to Wt littermates for the majority of the bone parameters, except IDUA+/− females showed an increase in cortical density,
and IDUA+/− males showed an increase in trabecular density when
compared to Wt counterparts (Table 1). Genotype related changes in
trabecular density, thickness, or SMI were not observed at 16 weeks of
age (Table 1). These data suggest that the IDUA−/− mutation alters
both the cortical and trabecular bone microarchitecture and appears
to be more pronounced in female mice.

2.6. Statistical analysis

3.3. Cortical density and porosity

All statistical analyses were performed using SAS (SAS Institute Inc.,
Cary, NC). Growth curves quantifying body weight were analyzed as
a repeated measures design (split plot and time) as outlined by
Littell et al. [26]. The ﬁxed effects were arranged as a 3 × 2 × 12 factorial
(3 genotypes × 2 sexes × 12 time points). The genotype, sex, and
genotype × sex interactions represent the main plot, and time and all
possible interactions with the main plot represent the subplot. The denominator of F for the main plot effect was the random effect, mouse
ID per given genotype and sex. The residual mean square was used to
test all subplot effects. Since this was a three-way interaction the differences between genotypes were tested for the two sexes keeping time
constant.
Bone microarchitecture, geometric parameters, and biomechanical
properties were evaluated by analysis of covariance with body weight
as the covariate, and the physiochemical parameters were evaluated
by analysis of variance by a 3 × 2 factorial (3 genotypes and 2 sexes).
Speciﬁcally, mean differences were determined using Fisher's Protected
Least Signiﬁcant Difference [27]. Fisher's Protected Least Signiﬁcant
Difference permits most comparisons to be orthogonal (independent)
using a contrast statement. Six preplanned pairwise comparisons were
analyzed. When heterogeneous variations made it necessary (p ≤ 0.05
as determined by Bartlett's test for homogeneity), a log transformation
was used to stabilize the variation. If the log transformation failed to

Quantitative back-scattered electron microscopy was used to evaluate the bone mineral density distribution (BMDD) at mid-diaphysis of
the mouse tibia. In bone, atomic number of the matrix is related to the
calcium content and therefore, areas which contain a higher concentration of calcium had a higher graylevel number, which for the Wt,
IDUA+/−, and IDUA−/− images (Fig. 3A, B & C) is indicated in orange
to red and the regions with the least mineralization (Lacunae and osteoid) are represented by the lower graylevel number and the color blue.
By quantitative backscattered scanning electron microscopy the BMDD
of female Wt and IDUA−/− tibias was equivalent (Fig. 3E–F), conﬁrming
the μCT cortical density ﬁndings (Table 1). Tibial porosity was deﬁned
and calculated as the area of pores (blue) divided by the area of the
bone. The quantiﬁcation indicated IDUA−/− tibial cortical bone porosity
was 50% greater than Wt, while the cortical porosity of the IDUA+/−
tibias were 12.2% greater than age and sex matched Wt littermates
(Fig. 3G).
3.4. Material composition
To investigate the material and physiochemical properties of the
cortical bone, Raman spectroscopy was performed to quantify speciﬁc
2−
components: phosphate (PO3−
4 ), carbonate (CO3 ), matrix (CH2) and
collagen (amide I). Tibiae from male Wt, IDUA+/−, and IDUA−/− mice
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Fig. 1. Weekly weighing demonstrated that A) male and B) female IDUA−/− (triangle) mice exhibited increased body weight compared to their Wt (circle) and IDUA+/− (square) littermates at 16 weeks of age. Mice were weighed weekly from 5–16 weeks of age. Values are the means of sex and genotype speciﬁc groups. * denotes IDUA−/− weight difference compared to
sex-matched Wt littermates and # denotes IDUA−/− weight difference compared to sex matched IDUA+/− littermates. Differences were considered signiﬁcant at p ≤ 0.05. Male Wt [week 5
(n = 6), weeks 6–16 (n = 10)], IDUA+/− [weeks 5–7 (n = 8), weeks 8–12 (n = 10), weeks 13–15 (n = 11), week 16 (n = 9)], and IDUA−/− [week 5 (n = 5), weeks 6–7 (n = 6), weeks
8–15 (n = 8), week 16 (n = 6)]; female Wt [week 5 (n = 8), weeks 6–7 (n = 9), weeks 8–12 (n = 11), weeks 13–15 (n = 12), week 16 (n = 10], IDUA+/− [week 5 (n = 14), weeks 6–16
(n = 15)], and IDUA−/− [week 5 (n = 4), weeks 6–16 (n = 6)].

amount of energy the bone absorbed prior to fracture, relative to Wt
femora (Fig. 6B). Male IDUA−/− femora showed a 16.2% increase in energy to failure relative to Wt, although did not reach signiﬁcance
(Fig. 6B). Torsional ultimate strength (Tmax) is a whole bone property
that measures the maximum amount of torque required to break the
bone. Femora from both male and female IDUA−/− mice exhibited increased Tmax compared to their Wt and IDUA+/− littermates. Tensile
strength, a measure of the strength of the bone material, was decreased
by 23.8% in female IDUA−/− femora as compared to Wt (Fig. 6D). In
male IDUA−/− mice, the femoral tensile strength was reduced 19.7%
as compared to Wt, however, the trend did not reach signiﬁcance
(p = 0.10). The torsional stiffness was not impacted by genotype
(Fig. 6E). However, shear modulus of elasticity, a measure of the stiffness of the bone material, was decreased in femora from IDUA−/− females compared to their Wt and IDUA+/− littermates (Fig. 6F). These
data suggest that the increased whole bone strength observed in femora
of IDUA−/− mice results from changes in the microarchitecture, geometry and the bone material properties. While the changes in bone geometry are predicted to increase strength, the changes in material
properties appear detrimental. Taken together, the impact of the absence of α-L-iduronidase activity on the biomechanical integrity of the
whole bone is the result of opposing forces of the impact of geometry
and bone material properties to produce an overall increase in torsional
strength. The IDUA bone is in a delicate balance of trying to maintain
skeletal integrity in the presence of compromised bone material.

did not show differences in material composition (Fig. 4). However, female IDUA−/− tibias exhibited increases in the carbonate/phosphate
(CO23 −/PO34 −) ratio (Fig. 4A) and decreases in phosphate/matrix
(PO34 −/CH2) (Fig. 4B), and had a lower phosphate:collagen (PO34 −/
amide I) ratio compared to Wt littermates, although it did not
reach signiﬁcance (p = 0.0647) (Fig. 4C). The phosphate:matrix and
phosphate:collagen ratios of female IDUA−/− tibias were decreased
compared to IDUA+/− littermates, as well, which were similar in composition to Wt.
3.5. Femoral geometry and biomechanical strength
Bone strength is cumulatively dictated by the interplay of the bone
geometry and the composition of the bone material. To determine if
the changes observed in bone microarchitecture and material properties altered the whole bone strength in IDUA−/− mice, we subjected
femora from male and female Wt, IDUA+/− and IDUA−/− mice to μCT
and torsional loading to failure. Both male and female IDUA−/− mice
had shorter femurs with 16% and 14% larger midshaft marrow diameters and 9% and 14% greater cortical bone widths compared to sexmatched Wt littermates, respectively (Fig. 5), which was consistent
with our observations of increased cortical thickness in the tibia
(Table 1). Male and female IDUA−/− femora both showed an increase
of 75% in their polar moment of area (a geometric predictor of increased
bone strength) as compared to sex-matched Wt littermates (Fig. 5).
Male and female Wt femora exhibit equivalent values for all the geometric parameters as sex-matched IDUA+/− femora. Femoral geometry
differences between sexes were observed in cortical bone width of Wt
mice, and the polar moment of area of Wt and IDUA+/− mice (Fig. 5).
To evaluate if the changes in bone microarchitecture, physiochemical composition, and geometry altered the overall strength of the
IDUA−/− bone, femora were subjected to torsional loading to failure. Female IDUA−/− femora exhibited 30.8% increase in energy to failure, the

4. Discussion
Although enzyme replacement and stem cell therapies for treating
MPS I have been effective in attenuating organomegaly, cardiac, respiratory and neurological symptoms of the lysosomal storage disorder MPS
I, the musculoskeletal manifestations are recalcitrant to current treatment strategies [9,11,17,30,31]. The goal of this study was to fully

Table 1
Tibial microarchitecture of 16 week old male and female Wt, IDUA+/− and IDUA−/− mice.
Male

Cortical density (mg HA/CCM)
Cortical thickness (mm)
Trabecular density (mg HA/CCM)
Trabecular BV/TV (%)
Trabecular Thickness (mm)
Trabecular SMI
a
b

p ≤ 0.05 compared to Wt.
p ≤ 0.05 compared to IDUA+/−.

Female

Wt
n=5

IDUA+/−
n=5

IDUA−/−
n = 4–5

Wt
n=3

IDUA+/−
n=4

IDUA−/−
n=5

1139.81 ± 11.91
0.210 ± 0.005
890.93 ± 21.90
0.227 ± 0.030
0.053 ± 0.004
1.607 ± 0.310

1123.46 ± 13.45
0.207 ± 0.003
930.08 ± 4.62a
0.228 ± 0.020
0.054 ± 0.003
1.76688 ± 0.199

1119.25 ± 3.52
0.250 ± 0.09a,b
927.86 ± 8.88
0.217 ± 0.031
0.049 ± 0.003
1.961 ± 0.227

1112.90 ± 8.42
0.195 ± 0.004
889.53 ± 8.30
0.077 ± 0.008
0.041 ± 0.001
3.026 ± 0.085

1142.28 ± 8.42a
0.195 ± 0.001
896.47 ± 2.10
0.075 ± 0.007
0.041 ± 0.001
2.789 ± 0.135

1118.86 ± 9.86b
0.237 ± 0.006a,b
908.12 ± 6.78
0.170 ± 0.021
0.047 ± 0.003
2.139 ± 0.123
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Fig. 2. Trabecular microarchitecture of male and female tibiae as determined by μCT. Representative images of A) Wt, B) IDUA+/−, and C) IDUA−/− μCT scans. D) Trabecular number was
increased in IDUA−/− tibiae (white bar) compared to sex-matched Wt (black bar) and IDUA+/− (gray bar) littermates. E) Trabecular separation was decreased in IDUA−/− females compared to sex-matched Wt and IDUA+/− littermates. F) Trabecular Connectivity was increased in IDUA−/− females compared to sex-matched Wt and IDUA+/−. Values are means ± SE.
a
p ≤ 0.05 compared to sex-matched Wt, bp ≤ 0.05 compared to sex-matched IDUA+/−, cp ≤ 0.05 compared to genotype-matched male. Male Wt (n = 5), IDUA+/− (n = 5), and
IDUA−/− (n = 4); Female Wt (n = 5), IDUA+/− (n = 4), and IDUA−/− (n = 5).

Fig. 3. Bone mineral density distribution (BMDD) and porosity analysis as determined by scanning electron microscopy. Representative segments of female A) Wt, B) IDUA+/−, and
C) IDUA−/− cross-sectional BMDD images of the medial section of the mid-diaphysis of the tibia (range of 256 graylevel numbers, with red representing the greatest density of calcium
and blue the least). For each sample the whole cross-sectional image was used to determine the BMDD histogram. D) Summation of all the histograms for each group shown based on the
frequency of graylevel numbers divided by the maximum frequency in each case. E) Averaged mode of graylevel histograms and F) the averaged full width at half maximum (FWHM)
values extracted from graylevel histograms were not different between genotypes. G) Porosity quantiﬁcation of Wt (black bar), IDUA+/− (gray bar) and IDUA−/− (white bar) showing
an increase in porosity in the IDUA−/− tibiae. Values are means ± SE. ap ≤ 0.05 compared to sex-matched Wt, bp ≤ 0.05 compared to sex-matched IDUA+/−. Wt (n = 5), IDUA+/−
(n = 5), and IDUA−/− (n = 4).
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Fig. 4. Physiochemical composition of the tibial cortical bone was determined using
3−
Raman spectroscopy. A) Carbonate/phosphate ratios [(CO2−
3 /PO4 ); indication of carbonate substitution of phosphate in the crystal lattice] were increased in tibiae from IDUA−/−
females (white bar) compared to Wt (black bar). B) Phosphate to bone matrix ratios
[(PO3−
4 /CH2); indication of the relative amount of mineral phosphate to organic matrix]
was decreased in tibiae from IDUA−/− females compared to Wt and IDUA+/− (gray bar)
littermates of the same sex. C) Phosphate to collagen ratios [(PO3−
4 /amide I); indication
of the relative amount of phosphate mineral to collagen] was decreased in tibiae from fe−/−
+/−
male IDUA
compared to IDUA
littermates and had a decreased trend compared to
sex-matched Wt littermates (p = 0.06). Values are means ± SE. ap ≤ 0.05 compared to
b
sex-matched Wt, p ≤ 0.05 compared to sex-matched IDUA+/−, cp ≤ 0.05 compared to genotype-matched male. Male Wt (n = 5), IDUA+/− (n = 5), and IDUA−/− (n = 4); Female
Wt (n = 5), IDUA+/− (n = 4), and IDUA−/− (n = 5).

characterize the skeletal geometry, microarchitecture, biomechanical and
physiochemical properties of the Idua-W392X knock-in (IDUA−/−)
mouse model of MPS I in order to better understand the consequences
of α-L-iduronidase enzyme deﬁciency and subsequent accumulation of
GAGs to skeletal integrity. Our ﬁndings suggest that complete absence
of α-L-iduronidase results in changes not only to the macro- and

microarchitecture of cortical and trabecular bone, but also to the physiochemical composition and porosity. These changes while opposing, ultimately culminate in an overall increase in whole bone strength. As
anticipated with autosomal recessive metabolic disorders, the IDUA+/−
mice were primarily unaffected and the skeletal integrity of their long
bones was equivalent to their Wt littermates.
It has been repeatedly demonstrated that patients with Hurler syndrome have decreased growth velocity and short stature which persists
following hematopoietic stem cell replacement therapy [32]. Both parameters contribute to and are indirect measures of the pathologic
and biochemical alterations seen in Hurler syndrome. Our study demonstrates that the IDUA−/− mice have decreased femur length and are
heavier than Wt and IDUA+/− littermates at 16 weeks of age, as has
been seen in untreated human patients, and previously in IDUA−/−
mice [15,21] as well as other mouse models of MPS [29,33,34]. It is likely
that the decreased height observed in Hurler syndrome patients may be
attributed to abnormalities in the growth plate caused by GAG accumulation [29,35,36]. The growth plates of IDUA−/− femora were shown to
have a 4-fold increase in osteoclast activity by tartrate-resistant acid
phosphatase histochemistry relative to wildtype femora [21]. Wilson
et al. demonstrated that Idua −/− knock-out mouse tibiae had twice
as much cartilage in the subepiphyseal zone of the growth plate, reduced type II collagen degradation, and ossiﬁcation as wildtype mouse
tibiae [37].
Our analysis of the tibial microarchitecture and geometry in
IDUA−/− mice at 16 weeks of age demonstrated increased cortical
thickness without changes in cortical density and were consistent
with studies in IDUA−/− mice [21], as well as the Idua−/− knockout
mice, which exhibited decreased femur length with a general thickening as measured by radiography [13,34], and shortening of the tibia
length, and increased femoral midshaft diameter without changes in
bone mineral density [34]. Additionally, we report an increase in the
femoral bone marrow diameter along with microarchitecture changes
in the trabecular bone of female IDUA−/− tibias. Consistent with studies
in other mouse models of MPS [38], the tibial trabecular bone of female
IDUA−/− mice showed an increase in trabecular number and connectivity density with a subsequent decrease in separation which suggests
overall increases in bone material and that the bone microarchitecture
has been altered by the deﬁciency in α-L-iduronidase. Studies by
Pievani et al. have demonstrated an increase in BV/TV in femora of an
Idua −/− knockout mouse model for MPS at 37 weeks of age [38],
whereas Gunn et al. found that 31 week old male IDUA−/− femora
had increased cortical thickness, trabecular BV/TV, number, and connectivity density, and decreased structural model index (SMI) and trabecular separation [21]. When female IDUA−/− tibiae were analyzed using
an ANOVA the BV/TV was increased as compared to their sex-matched
Wt and IDUA+/− littermates. However, when using body weight as a
co-variate the difference was no longer signiﬁcant (Table 1). This suggests that at 16 weeks, the increase in BV/TV in the tibiae of female
IDUA−/− mice can be attributed to a response to an increase in body
weight. The compromised bone material and the increased cortical porosity in the IDUA−/− mouse further suggests that these geometric
changes and the response of the microarchitecture may function to protect the integrity of the bone and/or simply reﬂect alterations in bone
remodeling.
Previous studies have implicated reductions in osteoclast number
and activity in MPS, speciﬁcally that the accumulation of MPSassociated GAGs (dermatan sulfate and heparin sulfate) may inhibit
the collagenolytic activity and osteoclast function [37] as well as increase the number of osteoblasts in the intertrabecular spaces [29].
However, Gunn et al. reported a 4-fold elevation in osteoclast activity
in the growth plates of femurs of 31 week old IDUA−/− mice relative
to wildtype femoral growth plates [21]. In a recent study of serum and
urine bone formation and resorption biomarkers, Stevenson et al.
found that children with MPS had elevated serum osteocalcin levels
and trends of increased serum bone speciﬁc alkaline phosphatase
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Fig. 5. Geometric parameters and polar moment of area of male and female Wt, IDUA+/−, and IDUA−/− femora as determined by μCT. A) Femoral length was decreased, and B) marrow
diameter, C) cortical bone width, and D) polar moment of area were increased in IDUA−/− femurs (white bar) compared to sex-matched Wt (black bar) and IDUA+/− (gray bar) femora.
Values are means ± SE. ap ≤ 0.05 compared to sex-matched Wt, bp ≤ 0.05 compared to sex-matched IDUA+/−, cp ≤ 0.05 compared to genotype-matched male. Male Wt (n = 10), IDUA+/−
(n = 9), and IDUA−/− (n = 11); Female Wt (n = 7), IDUA+/− (n = 7), and IDUA−/− (n = 10).

compared to age and tanner-stage matched unaffected children [39],
suggesting that children with MPS may have increased osteoblast activity. In the IDUA−/− mice the increased porosity per bone volume is indicative of increased osteocyte lacunae, which potentially reﬂects
increased osteoblasts which likely have compromised function resulting
in the formation of poorer quality bone. In addition, the increase in carbonate to phosphate ratios in the female IDUA−/− tibia suggests a more
mature matrix and perhaps decreased degradation. Taken together
these ﬁndings and ours further suggest that the pathogenesis of the
musculoskeletal manifestations in MPS is associated with abnormal
bone remodeling. Future studies to investigate osteoblast, osteoclast
and osteocyte function, bone remodeling efﬁciency, and dynamic and
static histomorphometry are necessary to further elucidate this
mechanism.
Bone is a composite of organic matrix and mineral; the mineral component, hydroxyapatite, provides stiffness, while the organic component is 80% collagen, of which 95% is type I collagen [40], and imparts
material toughness (the capacity to absorb energy) [41]. Together, the
abundance, quality and proportion of these components impact the
overall structural integrity of the bone. Bone strength is dependent
upon the cumulative contributions of the integrity of the bone material,
microarchitecture and geometry. The results of the torsional loading to
failure in the IDUA−/− mice revealed an overall increase in strength as
measured by the whole bone parameters, torsional ultimate strength
and energy to failure, but also compromised bone material strength of
the IDUA−/− bone as measured by tensile strength and shear modulus
of elasticity. This would suggest that the increase in strength is a net

result of positive alterations in the microarchitecture and geometry of
the bone that are able to compensate for the adverse changes in the material and physiochemical composition.
Changes in extracellular matrix components have been implicated in
the skeletal pathology of multiple MPSs [39]. A recent study using a
different MPS-1 mouse model revealed that changes in extracellular
matrix components of the skeleton are a major pathology of the disease
which may be independent of GAG accumulation as decreased expression of type I collagen and other cartilaginous proteins occur before
the histologic changes are visualized at the growth plate [36]. We further used Raman spectroscopy to evaluate the bone physiochemistry
and demonstrated that female IDUA−/− mouse tibias have decreased
mineral to matrix ratios and a decreasing trend in mineral to collagen
ratios. It is unclear if the decreases in mineral to matrix and mineral to
collagen ratios in the cortical bone are reﬂective of decreases in mineral
content, or an increase in collagen content due to increases in collagen
expression or decreases in the efﬁciency of collagen degradation by
osteoclasts. The absence of differences in the bone mineral density distribution, as determined by quantitative back scattered scanning electron microscopy and cortical density, as determined by μCT analyses
suggest that the ratio shifts are not due to alterations in mineral content.
This ﬁnding is consistent with Wang et al. who reported that IDUA−/−
and WT bone mineral density (BMD) were equivalent at 5 and
15 weeks of age, but by 35 weeks of age the IDUA−/− had greater
BMD [15].
Deﬁning the underlying mechanical properties of the skeletal abnormalities is the ﬁrst step in elucidating the cellular and biochemical
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Fig. 6. Bone biomechanical integrity. A) Representative torsional loading to failure graphs from female Wt (black bar), IDUA+/− (gray bar), and IDUA−/− (white bar) femora. B) Energy to
failure (U; the amount of energy the bone can absorb prior to fracture as measured by the area under the torque: angular displacement graph) of female IDUA−/− femora is increased
compared to sex-matched Wt and IDUA+/− littermates. C) Torsional ultimate failure (Tmax; the force at failure as measured by the peak of the torque: angular displacement curve)
was increase in both male and female femora from IDUA−/− compared to sex-matched Wt and IDUA+/− littermates. D) Tensile strength (Su; the strength of the bone material as measured
by subtracting the estimated strength contribution of the geometry component from the Tmax) is decreased in femora from female IDUA−/− compared to sex-matched Wt littermates.
E) Torsional stiffness (Ks; the stiffness of the bone as measured by the slope of the torque: angular displacement curve between 5 and 10 Nmm) is equivalent among all genotypes assessed.
F) Shear modulus of elasticity (G; an estimate of the elasticity of the bone material as measured by the Ks—the estimated contribution of the geometry component) is reduced in femora
from female IDUA−/− compared to sex-matched WT and IDUA+/− littermates. ap ≤ 0.05 compared to sex-matched Wt, bp ≤ 0.05 compared to sex-matched IDUA+/−, cp ≤ 0.05 compared to
genotype-matched male. Male Wt (n = 8), IDUA+/− (n = 6), and IDUA−/− (n = 7); Female Wt (n = 8), IDUA+/− (n = 8), and IDUA−/− (n = 5).
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processes responsible for MPS I-H skeletal phenotype which will inform
the improvement of current therapies and uncover potential therapeutic targets for the development of new therapies to further improve the
bone quality of MPS I-H patients.
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